Your browser doesn't support javascript.
loading
Comparing outcomes of transcatheter tricuspid valve replacement and medical therapy for symptomatic severe tricuspid regurgitation: a retrospective study.
Wang, Yiwei; Liu, Yang; Meng, Xin; Zhai, Mengen; Jin, Ping; Lu, Fanglin; Yang, Jian.
Affiliation
  • Wang Y; Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 127 Changle West Road, Xi'an, 710032, Shaanxi, China.
  • Liu Y; Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 127 Changle West Road, Xi'an, 710032, Shaanxi, China.
  • Meng X; Department of Ultrasound Medicine, Xijing Hospital, Air Force Medical University, Xi'an, 710032, Shaanxi, China.
  • Zhai M; Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 127 Changle West Road, Xi'an, 710032, Shaanxi, China.
  • Jin P; Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 127 Changle West Road, Xi'an, 710032, Shaanxi, China.
  • Lu F; Department of Cardiovascular Surgery, Shanghai General Hospital, Shanghai Jiaotong University, 100 Haining Road, Shanghai, 201620, China. drlufanglin@yeah.net.
  • Yang J; Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, 127 Changle West Road, Xi'an, 710032, Shaanxi, China. yangjian1212@hotmail.com.
Eur J Med Res ; 29(1): 407, 2024 Aug 05.
Article in En | MEDLINE | ID: mdl-39103966
ABSTRACT

BACKGROUND:

Impaired hospitalizations for heart failure (HHF) and mortality are associated with tricuspid regurgitation (TR).

OBJECTIVES:

The objective of this study was to investigate the benefit of transcatheter tricuspid valve replacement (TTVR) over guideline-directed medical therapy (GDMT) in patients with symptomatic severe TR.

METHODS:

Between May 2020 and April 2023, 88 patients with symptomatic severe TR were treated in our center. Of these, 57 patients received GDMT alone, and 31 patients underwent combined TTVR and GDMT. We collected and analyzed baseline data, and follow-up information for both groups. The primary endpoints were all-cause mortality and the combined endpoint (including all-cause mortality and HHF).

RESULTS:

At a median follow-up of 20 (IQR 10-29) months, significant improvements were shown in TR severity, right ventricular function, and dimensions in TTVR group (all P < 0.001). It also resulted in superior survival rates (75.8% vs. 48.4%, P = 0.019), improved freedom from combined endpoint (61.5% vs. 45.9%, P = 0.007) and fewer major adverse events. After stratification by TRI-SCORE, the subgroup with < 6 points in the TTVR group exhibited a significant difference in the combined endpoint compared to the other subgroups (all P < 0.05), while no significant differences were observed in the GDMT subgroups (P = 0.680).

CONCLUSIONS:

The utilization of LuX-Valve in TTVR effectively improves TR and is associated with lower rates of major adverse events, HHF and all-cause mortality. The TRI-SCORE may help identify higher-benefit patients with TR from TTVR. Clinical trial registration ClinicalTrials.gov Protocol Registration System (NCT02917980).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tricuspid Valve Insufficiency / Heart Valve Prosthesis Implantation Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur J Med Res Journal subject: MEDICINA Year: 2024 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tricuspid Valve Insufficiency / Heart Valve Prosthesis Implantation Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur J Med Res Journal subject: MEDICINA Year: 2024 Document type: Article Affiliation country: China